Incidence of psychiatric side effects during pegylated interferon- alpha retreatment in nonresponder hepatitis C virus-infected patients.

Abstract

OBJECTIVE:

Evaluate the incidence of mental disorders using pegylated interferon plus ribavirin retreatment in nonresponder hepatitis C virus-infected patients.

METHOD:

The Mini-International Neuropsychiatric Interview (MINI) was used to evaluate 30 hepatitis C virus-infected interferon-nonresponder patients at baseline and following 4, 12 and 24 weeks of pegylated interferon retreatment.

RESULTS:

During the pegylated interferon/ribavirin retreatment, 5(16.6%) patients developed psychiatric side effects: 3(10%) were diagnosed with major depressive disorder, 1(3.3%) had a brief psychotic disorder and 1(3.3%) presented with panic attacks.

CONCLUSION:

This is the first prospective study evaluating the incidence of neuropsychiatric side effects during interferon retreatment of hepatitis C virus-infected patients, suggesting that the risk of acquiring serious psychiatric symptoms during retreatment with interferon-alpha (IFN-alpha) may not be higher than during the first antiviral therapy. This finding challenges the hypothesis that during a second treatment with IFN-alpha, patients with hepatitis C may be at greater risk for neuropsychiatric side effects than naïve patients.

• Authors: Lucas C Quarantini, Rodrigo A Bressan, Amanda Galvão, Susana Batista-Neves, Raymundo Paraná, Angela Miranda-Scippa
• Journal: Liver international : official journal of the International Association for the Study of the Liver (Liver Int) Vol. 27 Issue 8 Pg. 1098-102 (Oct 2007) ISSN: 1478-3223 [Print] United States
• PMID: 17845538 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Anxiety Agents
• Antidepressive Agents
• Antipsychotic Agents
• Antiviral Agents
• Interferon alpha-2
• Interferon-alpha
• Recombinant Proteins
• Polyethylene Glycols
• Ribavirin
• peginterferon alfa-2b
• peginterferon alfa-2a

Topics

• Adult
• Anti-Anxiety Agents (therapeutic use)
• Antidepressive Agents (therapeutic use)
• Antipsychotic Agents (therapeutic use)
• Antiviral Agents (adverse effects)
• Depressive Disorder, Major (chemically induced, drug therapy, epidemiology)
• Drug Therapy, Combination
• Female
• Hepatitis C (drug therapy)
• Humans
• Incidence
• Interferon alpha-2
• Interferon-alpha (adverse effects)
• Male
• Middle Aged
• Panic Disorder (chemically induced, drug therapy, epidemiology)
• Polyethylene Glycols (adverse effects)
• Prospective Studies
• Psychiatric Status Rating Scales
• Psychotic Disorders (drug therapy, epidemiology, etiology)
• Recombinant Proteins
• Ribavirin (adverse effects)
• Risk Assessment
• Risk Factors
• Time Factors
• Treatment Failure